Sibeprenlimab Receives U.S. FDA Breakthrough Therapy Designation for the Treatment of Immunoglobulin

PRINCETON, N.J. & TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc., (OPDC); Otsuka Pharmaceutical, Co. Ltd. (Otsuka); and Visterra, Inc., an Otsuka group company announce that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designat...

Related Keywords

Japan ,Tokyo ,Robert Murphy ,John Kraus ,Barrattj Ig ,Jeffrey Gilbert ,Brian Jg Pereira ,Christopher Kiefer ,Otsuka Holdings Co Ltd ,Twitter ,Corporate Communications ,Visterra Inc ,Linkedin ,Glomerular Diseases Work Group ,Otsuka Pharmaceutical Co Ltd ,Otsuka America Inc ,Drug Administration ,Otsuka Pharmaceutical Company Ltd ,Otsuka America Pharmaceutical Inc ,Otsuka Pharmaceutical Development Commercialization Inc ,Otsuka Pharmaceutical Development ,Otsuka Pharmaceutical ,Breakthrough Therapy ,New England Journal ,Biological Licensing Application ,Proliferation Inducing Ligand ,Otsuka America Pharmaceutical ,Otsuka Pharmaceutical Company ,Otsuka America ,Immune Modulation ,Iga Nephropathy ,Neutralizing Igg ,Kidney Int ,Patients From ,Southeastern United States With Iga ,Rev Dis ,Improving Global Outcomes ,Glomerular Diseases Work ,Practice Guideline ,America Pharmaceutical ,